Vanessa M. Lucey, Ph.D., MBA

Director, CRI Venture Fund and Clinical Accelerator
New York | Email | (212) 688-7515 x244

Vanessa M. Lucey, Ph.D., MBA, is the Director of CRI’s flagship program, the Clinical Accelerator and Venture Fund—a unique global collaboration of more than 90 of the field’s top clinical researchers and over 20 top biopharma companies designed to identify novel combinations of cancer immunotherapies that may hold transformational promise for patients. Vanessa leads and manages the program’s scientific and investment strategy for $110M+ evergreen venture fund. She also oversees and coordinates activities between our clinical trials management delivery partners, as well as various academic and biopharma stakeholders. Additionally, Vanessa manages the CRI IO Landscape, a drug and clinical trial database to track the evolving field of immunotherapy. 

Vanessa has 18 years of experience in the field of immunology and immunotherapy. She first joined CRI in 2014 after 12 years as a research scientist. She received her B.S. in biology from Fordham University, her Ph.D. from Albert Einstein College of Medicine, and completed her postdoctoral fellowship at NYU School of Medicine. Vanessa also holds an M.B.A. in Management/Finance from Mercy College School of Business. She has published 33+ peer-reviewed papers in top tier journals.

Select Publications

  • Tang J, Hubbard-Lucey VM, Pearce L, O’Donnell-Tormey J, Shalabi A. The global landscape of cancer cell therapy. Nature Reviews Drug Discovery. 10.1038/nrd.2018.74 (2018)  
  • Tang J, Shalabi A, Hubbard-Lucey VM. Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol. 2017 Dec 7. doi: 10.1093/annonc/mdx755. [Epub ahead of print]
  • Le DT, Hubbard-Lucey VM, Morse MA, Heery CR, Dwyer A, Marsilje TH, Brodsky AN, Chan E, Deming DA, Diaz LA, Fridman WH, Goldberg RM, Hamilton SR, Housseau F, Jaffee EM, Kang SP, Krishnamurthi SS, Lieu CH, Messersmith W, Sears CL, Segal NH, Yang A, Moss RA, Cha E, O'Donnell-Tormey J, Roach N, Davis AQD, McAbee KE, Worrall S, Benson AB. A Blueprint to Advance Colorectal Cancer Immunotherapies. Cancer Immunol Res. 2017 Oct 16. (PMID:29038296)
  • Mellman I, Hubbard-Lucey VM, Tontonoz MJ, Kalos MD, Chen DS, Allison JP, Drake CG, Levitsky H, Lonberg N, van der Burg SH, Fearon DT, Wherry EJ, Lowy I, Vonderheide RH, Hwu P. De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute.Cancer Immunol Res. 2016 Apr; 4 (4): 279-88. Review. (PMID: 27036972)
  • Hubbard-Lucey VM, Tontonoz MJ. Translating Science into Survival: Report on the Inaugural International Cancer Immunotherapy Conference. Cancer Immunol Res January 2016 4; 3.
  • Hubbard-Lucey VM, Shono Y, Maurer K, West ML, Singer NV, Ziegler CG, Lezcano C, Motta AC, Schmid K, Levi SM, Murphy GF, Liu C, Winkler JD, Amaravadi RK, Rogler G, Dickinson AM, Holler E, van den Brink MR, Cadwell K. Autophagy Gene Atg16l1 Prevents Lethal T Cell Alloreactivity Mediated by Dendritic Cells. Immunity 2014 Oct 8.
  • Diab A, Jenq RR, Rizzuto GA, Cohen AD, Huggins DW, Merghoub T, Engelhorn ME, Guevara-Patiño JA, Suh D, Hubbard-Lucey VM, Kochman AA, Chen S, Zhong H, Wolchok JD, van den Brink MR, Houghton AN, Perales MA. Enhanced responses to tumor immunization following total body irradiation are time-dependent. PLoS One 2013 Dec 12.
  • Hubbard VM, Valdor R, Patel B, Singh R, Cuervo AM, Macian F. Macroautophagy regulates energy metabolism during effector T cell activation. J Immunol 2010 Dec 15.
  • Hubbard VM, Eng JM, Ramirez-Montagut T, Tjoe KH, Muriglan SJ, Kochman AA, Terwey TH, Willis LM, Schiro R, Heller G, Murphy GF, Liu C, Alpdogan O, van den Brink MR. Absence of inducible costimulator on alloreactive T cells reduces graft versus host disease and induces Th2 deviation. Blood 2005 Nov 1.
Let's spread the word about Immunotherapy! Click to share this page with your community.

*Immunotherapy results may vary from patient to patient.

Top